BioPharma Management and Consulting financials
A multi-period view of the public annual-account figures reported for BioPharma Management and Consulting, with comparable measures and links to available source documents.
Company overviewRegistry number
0664691906
Fiscal coverage
2024–2025
Public sources
cbso_bulk
Data updated
Jul 28, 2026
Financial evidence
Latest movements for BioPharma Management and Consulting
2025 versus 2024
- Operating line
- €191,251
- EBITDA
- €181,032
- Total assets
- €3,160,210
- Equity
- €18,600
-16.7%
-15.6%
-3.4%
-44.4%
EBITDA margin +94.7% · Equity ratio +0.6%
Multi-year filings
Source: NBB/CBSOFiled annual accounts by fiscal year
Public regulator-filed figures across 2 years.
Fiscal year | Gross margin | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €191,251 | €181,032 | €3,160,210 | €18,600 | - |
| 202431 Dec 2024 | €229,502 | €214,396 | €3,269,904 | €33,469 | - |
Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.